These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Influence of tobacco on the serum levels and pharmacokinetics of phenylbutazone and oxyphenbutazone]. Queneau P, Ollagnier M, Decousus H, Perpoint B, Brazier JL, Faucon L. Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):293-7. PubMed ID: 6879097 [Abstract] [Full Text] [Related]
6. GLC determination of plasma concentration of phenylbutazone and its metabolite oxyphenbutazone. Midha KK, McGilveray IJ, Charette C. J Pharm Sci; 1974 Aug; 63(8):1234-9. PubMed ID: 4852201 [No Abstract] [Full Text] [Related]
7. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. Mealey KL, Matthews NS, Peck KE, Ray AC, Taylor TS. Am J Vet Res; 1997 Jan; 58(1):53-5. PubMed ID: 8989496 [Abstract] [Full Text] [Related]
8. Separation of furosemide, phenylbutazone and oxyphenbutazone in plasma by direct injection onto internal surface reversed-phase columns with systematic optimization of selectivity. Pinkerton TC, Perry JA, Rateike JD. J Chromatogr; 1986 Oct 03; 367(2):412-8. PubMed ID: 3782354 [No Abstract] [Full Text] [Related]
12. Plasma half-life of phenylbutazone in patients with impaired liver function. Hvidberg EF, Andreasen PB, Ranek L. Clin Pharmacol Ther; 1974 Feb 03; 15(2):171-7. PubMed ID: 4855829 [No Abstract] [Full Text] [Related]
13. Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC. Bruce RB, Maynard WR, Dunning LK. J Pharm Sci; 1974 Mar 03; 63(3):446-8. PubMed ID: 4820382 [No Abstract] [Full Text] [Related]
14. A supercritical fluid chromatographic method using packed columns for phenylbutazone and oxyphenbutazone in serum, and for phenylbutazone in a dosage form. Simmons BR, Jagota NK, Stewart JT. J Pharm Biomed Anal; 1995 Jan 03; 13(1):59-64. PubMed ID: 7718635 [Abstract] [Full Text] [Related]
15. Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. Chay S, Woods WE, Nugent TE, Weckman T, Houston T, Sprinkle F, Blake JW, Tobin T, Soma LR, Yocum J. J Vet Pharmacol Ther; 1984 Dec 03; 7(4):265-76. PubMed ID: 6512917 [Abstract] [Full Text] [Related]
16. Pharmacokinetics of phenylbutazone in neonatal foals. Wilcke JR, Crisman MV, Sams RA, Gerken DF. Am J Vet Res; 1993 Dec 03; 54(12):2064-7. PubMed ID: 8116939 [Abstract] [Full Text] [Related]
17. Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. Matthews NS, Peck KE, Taylor TS, Mealey KL. Am J Vet Res; 2001 May 03; 62(5):673-5. PubMed ID: 11341383 [Abstract] [Full Text] [Related]
18. Individual differences in the plasma half-lives of lipid soluble drugs in man. Davies DS, Thorgeirsson SS. Acta Pharmacol Toxicol (Copenh); 1971 May 03; 29 Suppl 3():181-90. PubMed ID: 5316400 [No Abstract] [Full Text] [Related]